GlassScriptPhysician profile
Charles Kersten
NPI 1013477926
$5,598.42
in general payments reported to CMS, 2019-2025
20 companies · $3,911 in 2025
The $3,911 reported for 2025 was more than what 88% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $41.12 · 2024: $1,647 · 2025: $3,911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,015 · Travel and Lodging: $2,533 · Education: $9.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,015.26 |
| Travel and Lodging | $2,532.50 |
| Education | $9.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,282.48 | 2024-2025 | Kyphon Express II Kyphopak Tray, Synchromedii, Inceptiv |
| Boston Scientific Corporation | $1,497.57 | 2025 | Wavewriter Alpha Prime 16, General - Pain Management, Intracept |
| Curonix LLC | $473.66 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Saluda Medical Americas, INC. | $252.54 | 2025 | Evoke |
| Painteq LLC | $168.79 | 2024 | Painteq |
| Biotronik Nro, INC. | $110.62 | 2025 | Prospera |
| Spr Therapeutics, INC | $102.58 | 2025 | Sprint Pns System |
| Pfizer INC. | $102.47 | 2024-2025 | |
| Stryker Corporation | $96.95 | 2025 | Optablate, Mild Device Kit |
| Abbott Laboratories | $89.43 | 2024-2025 | Proclaim, Eterna |
| Abbvie INC. | $78.26 | 2024-2025 | |
| Collegium Pharmaceutical, INC. | $71.89 | 2024-2025 | Belbuca, Xtampza |
| Scilex Pharmaceuticals INC. | $66.24 | 2024 | |
| Tactile Systems Technology INC | $47.17 | 2025 | Flexitouch Plus, Nimbl |
| Pacira Pharmaceuticals Incorporated | $41.12 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $34.70 | 2024 | Prialt |
| Averitas Pharma INC. | $33.03 | 2025 | Qutenza |
| Protega Pharmaceutials INC | $18.33 | 2024 | Roxybond |
| Lundbeck LLC | $16.29 | 2025 | Vyepti |
| Fidia Pharma USA INC. | $14.30 | 2025 | Hymovis, Triluron |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Kersten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.